Drug intelligence / Profile preview

xinning tablets

Development stage: Unknown
Lead developer: Jilin Province Baker Pharmaceutical
Administration: Oral

Overview

Xinning Tablets (心宁片) is a traditional Chinese medicine (TCM) oral formulation developed and manufactured by Jilin Province Oriental Pharmaceutical. It is approved in China for the treatment of coronary heart disease and angina pectoris. The medication is formulated to promote blood circulation, resolve blood stasis, and improve blood flow to the heart. It typically contains extracts from Hawthorn (Crataegus pinnatifida), Ginkgo biloba, and Pueraria lobata, which are known for their vasodilatory and antioxidant properties. In the context of TCM theory, it is used to treat chest obstruction caused by Qi stagnation and blood stasis, manifesting as chest tightness and heart pain.

Brand names: 心宁片Xinning Tablets
Other names: Xinning Pian

Beyond the preview

Go deeper on xinning tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xinning tablets.

Explore the full profile